VOLPARA HEALTH TECHNOLOGIES LIMITED (VHT)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
VHT - VOLPARA HEALTH TECHNOLOGIES LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.28
Index:
FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.28
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$1.135
28 Mar |
0.000 OPEN $1.13 |
0.000 HIGH $1.14 |
539,358 LOW $1.13 |
TARGET | |||||
|
OTHER COMPANIES IN THE SAME SECTOR | |||
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY24 Forecast |
FY25 Forecast |
---|---|---|
EPS (cps) | - 2.0 | xxx |
DPS (cps) | 0.0 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | N/A | xxx |
Dividend Yield | 0.0% | xxx |
Div Pay Ratio(%) | N/A | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.5 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 31.9 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 18.8 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -3.5 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -27.99 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -17.60 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -17.06 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -11.99 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -17.60 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -22.36 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -3.5 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 20 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 12 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 4.03 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 2.3 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 7.34 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 7 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 36 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 16 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
VHT STOCK CHART
FNArena News on VHT
1 |
Rudi’s View: CBA, GQG, Pilbara Minerals, Sonic Healthcare, Webjet & XeroMar 14 2024 - Rudi's View |
2 |
Rudi’s View: Week 3 – Not As Good, But Not BadFeb 28 2024 - Rudi's View |
3 |
Weekly Ratings, Targets, Forecast Changes – 15-12-23Dec 18 2023 - Weekly Reports |
4 |
FNArena Corporate Results Monitor – 29-05-2023May 29 2023 - Australia |
5 |
Australian Broker Call *Extra* Edition – Jan 25, 2023Jan 25 2023 - Daily Market Reports |
Latest Medical Equipment & Devices News
1 |
Uptrend Resumed For ResMedMar 19 2024 - Technicals |
2 |
Dr Boreham’s Crucible: CochlearFeb 28 2024 - Australia |
3 |
Rudi Interviewed: Ongoing Potential In Technology & GrowthFeb 19 2024 - Rudi's View |
4 |
Dr Boreham’s Crucible: ArtryaFeb 15 2024 - Small Caps |
5 |
ResMed Recovery Turns Into Hollywood ScriptJan 31 2024 - Australia |
6 |
ResMed Makes A ComebackJan 29 2024 - Australia |
7 |
ResMed: The Recovery Has BegunJan 23 2024 - Technicals |
8 |
Dr Boreham’s Crucible: Pro MedicusOct 23 2023 - Australia |
9 |
Dr Boreham’s Crucible: CyclopharmOct 09 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |